

Media Statement

13 July 2020

For immediate release

3Sixty Biopharmaceuticals Partners with Jubilant Generics to supply Remdesivir IV in Southern Africa

3Sixty Biopharmaceuticals (Pty) Ltd (3Sixty Biopharma), a division of 3Sixty Global Solutions Group (3SixtyGSG) has partnered with Jubilant Generics, a subsidiary of Jubilant life sciences Limited to supply Remdesivir for the treatment of COVID-19 infection in Southern Africa. On the 12th May 2020, Jubilant Life Sciences entered into Licensing Agreement with Gilead for Remdesivir, a potential therapy for Covid-19. Jubilant has recently signed a distribution Agreement with 3Sixty Biopharma to supply the local market.

This partnership is signed at the time when the body of evidence supporting the use of Remdesivir is growing. Data presented at COVID-19 Conference as part of the 23rd International AIDS Conference (AIDS 2020: Virtual) indicates promising results highlighting the safety and efficacy of this experimental treatment. This partnership is part of a broader 3Sixty GSG strategy to leverage its commercial and research partnerships to make life saving medications available to treat Covid-19.

The first shipment for Remdesivir arrives in the country in August and there has been strong interest registered by the private sector operators, engagement with the State have also started and we expect the State to show strong interest in the drug. The arrival of Remdesivir will herald a new chapter in the treatment of Covid-19 with the introduction of a drug to treat the virus at the time that we are entering a peak infection period which is proving unbearable to our healthcare infrastructure.

About Remdesivir

Remdesivir is an antiviral product that is being studied in multiple ongoing international clinical trials. In recognition of the current public health emergency and based on available clinical data, the approval status of Remdesivir varies by country. In countries where Remdesivir has not been approved by the regional health authority, Remdesivir is an investigational drug, and the safety and efficacy of Remdesivir have not been established.

About 3Sixty Biopharmaceuticals (Pty) Ltd

3Sixty Biopharmaceuticals (Pty) Ltd is a South African company based in Johannesburg, the commercial hub of South Africa. The company is committed to the development and commercialisation of South African and international intellectual property and it seeks to achieve this either by itself or through collaboration with principals both from the private and/or public sector. 3Sixty Biopharma is a subsidiary of the 3Sixty Global Solutions Group.

About 3Sixty Global Solutions Group (3Sixty GSG)

The 3Sixty Global Solutions Group (**3Sixty GSG**), a subsidiary of NUMSA Investment Company. 3Sixty GSG evolved from Doves Group, a funeral services company into the most integrated financial services group offering life insurance through 3Sixty Life, medical aid administration through 3Sixty Health which administers Sizwe Medical Fund, retirement fund administration through SALT Employee Benefits and asset management through Qumulate Asset Management, the Group has a number of support companies that are market facing on behalf of its product companies. The Group has diversified into Biotechnology initiating 4 start-ups in classical

Directors: Khandani Msibi (CEO) Mahlubi Mazwi (CFO) Minki Rasenyalo, Tebogo Moshakga (Company Secretary)

pharmaceutical, biological medicines, nuclear medicine and medical equipment. The Group is investing heavily in Biotechnology in partnership with local and international companies and agencies to find novel solutions to solve old and new problems for the local and international market.

Issued by 3Sixty GSG.

For more information, please contact:

Sandra Hlungwani, 3Sixty GSG Communications Manager: 063 897 8428